Lytix partner Verrica Phase II data show VP-315 abscopal effect in basal cell carcinoma

Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc.

VRCA

0.00
  • Lytix Biopharma announced new Phase II data on ruxotemitide (VP-315) in basal cell carcinoma will be presented at Society for Investigative Dermatology annual meeting in Chicago on May 15, 2026.
  • Results indicate treatment of injected tumors was linked to shrinkage in separate, non-injected lesions, supporting a potential abscopal effect consistent with broader immune activation.
  • Readout strengthens clinical rationale for ruxotemitide beyond local tumor control, supporting development in settings where pre-surgical immune priming could add value.
  • Partner Verrica is advancing VP-315 toward Phase III studies in basal cell carcinoma, while Lytix expects top-line results from NeoLIPA Phase II neoadjuvant melanoma study in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.